TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
MARKET SHARE 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Substitutes 20
Rivalry 21
LEADING COMPANIES 22
Johnson & Johnson 22
Novartis AG 27
Omega Pharma NV 31
MARKET DISTRIBUTION 35
MARKET FORECASTS 36
Market value forecast 36
MACROECONOMIC INDICATORS 37
APPENDIX 39
Methodology 39
Industry associations 40
Related Datamonitor research 40
Disclaimer 42
ABOUT DATAMONITOR 43
Premium Reports 43
Summary Reports 43
Datamonitor consulting 43
LIST OF TABLES
Table 1: Belgium OTC pharmaceuticals market value: $ million, 2005–09 10
Table 2: Belgium OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Table 3: Belgium OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Table 4: Belgium OTC pharmaceuticals market share: % share, by value, 2009 13
Table 5: Johnson & Johnson: key facts 22
Table 6: Johnson & Johnson: key financials ($) 24
Table 7: Johnson & Johnson: key financial ratios 25
Table 8: Novartis AG: key facts 27
Table 9: Novartis AG: key financials ($) 29
Table 10: Novartis AG: key financial ratios 29
Table 11: Omega Pharma NV: key facts 31
Table 12: Omega Pharma NV: key financials ($) 32
Table 13: Omega Pharma NV: key financials (€) 33
Table 14: Omega Pharma NV: key financial ratios 33
Table 15: Belgium OTC pharmaceuticals market distribution: % share, by value, 2009 35
Table 16: Belgium OTC pharmaceuticals market value forecast: $ million, 2009–14 36
Table 17: Belgium size of population (million), 2005–09 37
Table 18: Belgium gdp (constant 2000 prices, $ billion), 2005–09 37
Table 19: Belgium gdp (current prices, $ billion), 2005–09 37
Table 20: Belgium inflation, 2005–09 38
Table 21: Belgium consumer price index (absolute), 2005–09 38
Table 22: Belgium exchange rate, 2005–09 38
LIST OF FIGURES
Figure 1: Belgium OTC pharmaceuticals market value: $ million, 2005–09 10
Figure 2: Belgium OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Figure 3: Belgium OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Figure 4: Belgium OTC pharmaceuticals market share: % share, by value, 2009 13
Figure 5: Forces driving competition in the OTC pharmaceuticals market in Belgium, 2009 14
Figure 6: Drivers of buyer power in the OTC pharmaceuticals market in Belgium, 2009 16
Figure 7: Drivers of supplier power in the OTC pharmaceuticals market in Belgium, 2009 17
Figure 8: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Belgium, 2009 18
Figure 9: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Belgium, 2009 20
Figure 10: Drivers of degree of rivalry in the OTC pharmaceuticals market in Belgium, 2009 21
Figure 11: Johnson & Johnson: revenues & profitability 25
Figure 12: Johnson & Johnson: assets & liabilities 26
Figure 13: Novartis AG: revenues & profitability 30
Figure 14: Novartis AG: assets & liabilities 30
Figure 15: Omega Pharma NV: revenues & profitability 34
Figure 16: Omega Pharma NV: assets & liabilities 34
Figure 17: Belgium OTC pharmaceuticals market distribution: % share, by value, 2009 35
Figure 18: Belgium OTC pharmaceuticals market value forecast: $ million, 2009–14 36
[Cerrar la tabla de contenidos]
